Proper Name: Alpha1-Proteinase Inhibitor (Human)
Manufacturer: Aventis Behring LLC, License #1281
- Chronic augmentation and maintenance therapy in individuals with alpha1-proteinase inhibitor deficiency and evidence of emphysema
July 8, 2003 Approval Letter - Zemaira
STN 125078/0, indicated for use as chronic augmentation and maintenance therapy in individuals with alpha1-proteinase inhibitor deficiency and evidence of emphysema.
Summary Basis for Regulatory Action - Zemaira(PDF - 1.9MB)
FDA Online Label Repository
Search this database for drug labeling and other information. The content has not been altered or verified by the FDA and may not be the labeling on currently distributed products or identical to the labeling that is approved.